Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611

Inclusion Criteria: * Healthy Caucasian males between 18 and 50 years (inclusive) of age * Normal body weight * Subjects with negative urinary drugs of abuse, HIV, Hepatitis B or Hepatitis C serology tests * Subjects must be able to adhere to the protocol requirements * Subjects must provide written informed consent to participate in the study. * Haemoglobin level \>12.5 mg /dl Exclusion Criteria: * History of significant psychiatric disorder, neurological diseases or sleep disorders * History of significant systemic diseases, by medical history or tests performed during screening examinations * Clinically significant laboratory tests at screening * History of drug or alcohol abuse. * Allergy to levodopa, carbidopa or any inactive component of the test formulation. * Subjects with dark skin * Subjects with skin diseases or neoplasms * Subjects with narrow-angle glaucoma * Subjects with significant allergic response to other drugs. * Subject with known atopic disorders * Known allergy or hypersensitivity to adhesive tapes. * Use of any prescription or over-the-counter (OTC) medications * Subjects who donated blood or received blood, in the last 3 months * Participation in another clinical trial in the last 30 days * Subjects which do not have the ability to communicate well or will not adhere to the protocol procedures